About Us
Advancing how women's health conditions are diagnosed
Millions of women experience prolonged diagnostic delays for conditions that affect quality of life, fertility decisions, and long-term health. Endometriosis alone can take 7 to 10 years to diagnose and currently requires surgical confirmation.
Veridyn is building rigorous molecular diagnostics designed to shorten that path.
Endometriosis is the first focus. The long-term vision extends to additional underdiagnosed women's health conditions, with the goal of meeting full U.S. and international regulatory standards so these diagnostics can be widely available, trusted across healthcare systems, and accessible to more patients over time.
Precision diagnostics built for real-world healthcare
To redefine how underdiagnosed women's health conditions are identified by building precision diagnostics that are rigorous, accessible, and ready for real-world healthcare.
Our approach works within existing clinical workflows, using specimens already collected in routine care. The aim is to provide earlier answers without adding invasive procedures or delays.
Earlier answers.
No new procedures.
No delays.
Women's health deserves the same diagnostic rigor applied to oncology, cardiology, and infectious disease.
Veridyn exists to raise that standard. Every assay is built with the expectation that it must withstand scrutiny, replication, and real-world use.
The principles that guide every decision
Science Before Scale
In biotechnology, there is often pressure to move quickly from discovery to product. At Veridyn, progress is tied to evidence. Before anything moves forward, results must be reproducible, independently validated, and strong enough to support real-world use. Expansion follows proof.
Designed for Clinical Reality
A test only helps if doctors can actually use it. That is why we focus on specimens already collected during routine care and technologies laboratories already understand. The goal is adoption, not novelty for its own sake.
Responsible Growth
Every dollar raised is directed toward clearly defined scientific milestones. We build in stages. Each phase must demonstrate measurable progress before moving forward. This protects patients, supporters, and the integrity of the science.
Quality Integrated Early
Quality is not an afterthought. Regulatory standards and documentation are built into the process from the beginning. That means fewer surprises later and a smoother path to clinical use.
About the Founder
Building diagnostics that clinical systems trust
Randi Wood has spent over a decade developing molecular diagnostic tests within regulated clinical laboratory environments.
Her work has included building laboratories, designing validation frameworks, and implementing assays required to meet rigorous regulatory standards. These are the kinds of diagnostics physicians depend on to guide treatment decisions and healthcare systems rely on to operate safely and effectively.
Veridyn brings that same level of scientific rigor, regulatory discipline, and clinical integration to women's health.
The objective is straightforward. Develop diagnostics that are reproducible, clinically deployable, and trusted across the healthcare system.
Every choice has been intentional
The Samples We Use
We prioritize specimens your doctor already collects during routine care. Adding new procedures creates friction. If a test requires doctors to change how they practice, it becomes a barrier to clinical adoption. Our work is designed to fit into real-world healthcare, not disrupt it.
The Technology
We select molecular approaches that laboratories can run reliably and healthcare systems understand. Practicality matters. A diagnostic only helps patients if it can be used widely.
How We Build
Diagnostic science can look promising early. What matters is whether it still works after deeper testing, independent review, and real-world conditions. We design development in stages so each phase must demonstrate strength before the next begins.